Amplyx Pharmaceuticals, Inc.

Basilea Pharmaceutica Ltd. has secured a transformational approval across the Atlantic for Zevtera nearly 15 years after the US Food and Drug Administration rejected the Swiss biotech's antibiotic. T

After a busy 2023 on the business development front, Basilea Pharmaceutica Ltd. has started the year by adding more assets to its pipeline with the acquisition of a preclinical antibiotics program f

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lenz/Graphite Combination Is All-Stock

Roche Holding AG , Genentech, Inc. and their affiliated companies were the busiest deal makers in the biopharmaceutical sector for the second consecutive year in 2021, with 23 deals across all cate